Arcus Biosciences, Inc.

NYSE:RCUS Stock Report

Market Cap: US$1.4b

Arcus Biosciences Management

Management criteria checks 2/4

Arcus Biosciences' CEO is Terry Rosen, appointed in May 2015, has a tenure of 9.58 years. total yearly compensation is $10.12M, comprised of 6.4% salary and 93.6% bonuses, including company stock and options. directly owns 3.12% of the company’s shares, worth $44.32M. The average tenure of the management team and the board of directors is 4.3 years and 4.8 years respectively.

Key information

Terry Rosen

Chief executive officer

US$10.1m

Total compensation

CEO salary percentage6.4%
CEO tenure9.6yrs
CEO ownership3.1%
Management average tenure4.3yrs
Board average tenure4.8yrs

Recent management updates

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS)

Dec 12
Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS)

Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking

Nov 21
Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking

Arcus Biosciences: Advancing On Several Fronts

Oct 29

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Sep 23

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 15
Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Aug 19
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

May 10
Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18
Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Dec 15

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Nov 30
Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 20

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Aug 29

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08
Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05
Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

CEO Compensation Analysis

How has Terry Rosen's remuneration changed compared to Arcus Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$270m

Jun 30 2024n/an/a

-US$249m

Mar 31 2024n/an/a

-US$231m

Dec 31 2023US$10mUS$650k

-US$307m

Sep 30 2023n/an/a

-US$293m

Jun 30 2023n/an/a

-US$287m

Mar 31 2023n/an/a

-US$279m

Dec 31 2022US$9mUS$350k

-US$267m

Sep 30 2022n/an/a

US$80m

Jun 30 2022n/an/a

US$67m

Mar 31 2022n/an/a

US$58m

Dec 31 2021US$9mUS$367k

US$53m

Sep 30 2021n/an/a

-US$278m

Jun 30 2021n/an/a

-US$199m

Mar 31 2021n/an/a

-US$168m

Dec 31 2020US$6mUS$326k

-US$123m

Sep 30 2020n/an/a

-US$88m

Jun 30 2020n/an/a

-US$112m

Mar 31 2020n/an/a

-US$95m

Dec 31 2019US$2mUS$340k

-US$85m

Sep 30 2019n/an/a

-US$80m

Jun 30 2019n/an/a

-US$69m

Mar 31 2019n/an/a

-US$54m

Dec 31 2018US$1mUS$295k

-US$50m

Sep 30 2018n/an/a

-US$51m

Jun 30 2018n/an/a

-US$63m

Mar 31 2018n/an/a

-US$59m

Dec 31 2017US$427kUS$315k

-US$53m

Compensation vs Market: Terry's total compensation ($USD10.12M) is above average for companies of similar size in the US market ($USD5.51M).

Compensation vs Earnings: Terry's compensation has increased whilst the company is unprofitable.

CEO

Terry Rosen (64 yo)

9.6yrs

Tenure

US$10,120,945

Compensation

Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has been the Chairman of...

Leadership Team

NamePositionTenureCompensationOwnership
Terry Rosen
Co-Founder9.6yrsUS$10.12m3.12%
$ 44.3m
Juan Jaen
Co- Founder & President9.6yrsUS$4.75m1.57%
$ 22.3m
Robert Goeltz
Principal Financial Officer & CFO4.3yrsUS$3.59m0.025%
$ 360.1k
Jennifer Jarrett
Chief Operating Officer4.2yrsUS$4.74m0.11%
$ 1.6m
Dimitry Nuyten
Chief Medical Officer2.3yrsUS$3.69m0.031%
$ 438.2k
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Alexander Azoy
VP of Finance & Principal Accounting Officer1.8yrsno data0.0064%
$ 90.5k
Jonathan Yingling
Chief Scientific Officer3.9yrsno datano data
Pia Eaves
Vice President of Investor Relations & Strategyno datano datano data
Carolyn Tang
General Counsel & Corporate Secretary6.3yrsUS$2.92m0.062%
$ 874.2k
Holli Kolkey
Vice President of Corporate Communicationsno datano datano data
Yvonne Gehring
Senior Vice President of Human Resources & Operationsno datano datano data

4.3yrs

Average Tenure

52yo

Average Age

Experienced Management: RCUS's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Terry Rosen
Co-Founder9.7yrsUS$10.12m3.12%
$ 44.3m
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Yasunori Kaneko
Lead Independent Director9.6yrsUS$503.21k0.16%
$ 2.3m
Kathryn Falberg
Independent Director7.3yrsUS$479.08k0.16%
$ 2.3m
Andrew Perlman
Independent Director4yrsUS$455.83k0.023%
$ 324.4k
Jeffrey Bluestone
Chairman of Scientific Advisory Boardno datano datano data
C. Machado
Independent Director5yrsUS$455.83k0.018%
$ 262.0k
David Lacey
Independent Director & Member of Scientific Advisory Board4.6yrsUS$500.83k0.054%
$ 763.4k
Antoni Ribas
Independent Director & Member of Scientific Advisory Board9.9yrsUS$470.83k0.033%
$ 472.8k
Merdad Parsey
Director4.4yrsno datano data
Nicole Lambert
Independent Director3.3yrsUS$450.83k0.015%
$ 217.4k
Stefani Spranger
Member of Scientific Advisory Board4.3yrsno datano data

4.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: RCUS's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 12:01
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arcus Biosciences, Inc. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Zhiqiang ShuBerenberg
Jason ZemanskyBofA Global Research